The United States’ Food & Drug Administration is being forced to repeatedly address the same issue with ImmunityBio’s management. Ironically, the biopharma company’s addressable actions don’t offer a ...

IBRX's aggressive R&D spend, weak financials, and emerging competition from TAR-200 and cretostimogene pose risks to future ...

It remains unclear whether the planned trial will use Anktiva, and its timing and design are undisclosed. ・NantWorks led ...

ImmunityBio’s (IBRX) meteoric rise this year has forced short sellers betting against the cancer drug developer to record roughly $492M in paper losses in the first 12 trading days of 2026, Bloomberg ...

The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting the development, maintenance, and function of key immune cells—NK and CD8+ killer T cells—that are involved ...

The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting the development, maintenance, and function of key immune cells—NK and CD8+ killer T cells—that are involved ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

In the past week, ImmunityBio, Inc. received marketing authorization in the United Arab Emirates for ANKTIVA across BCG-unresponsive non-muscle invasive bladder cancer and metastatic non-small cell ...

ImmunityBio's sales grew 700% in 2025, with fourth-quarter revenue rising 20% quarter over quarter. These excellent results extend an incredible run of good news for the up-and-coming biotech stock.

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA) has authorized an expanded access ...

ImmunityBio (IBRX-1.49%), an immunity-focused biotech, closed Friday’s session at $6.45, down 12.13%. The stock is still up 63.29% in the past five days and 207.14% in the past month. Trading volume ...